Startseite › Eierstockkrebs › Oregon › Portland
Klinische Studien zu Eierstockkrebs in Portland, OR
27 Studien zu Eierstockkrebs suchen Teilnehmer an Standorten in und um Portland (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Teilnehmer gesuchtPhase 3
- Providence Cancer Institute, Portland
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Teilnehmer gesuchtPhase 2/3
- Oregon Health and Science University, Portland
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Teilnehmer gesuchtPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Research Site, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Teilnehmer gesuchtPhase 1/2
- Oregon Health & Science University (OHSU), Portland
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Teilnehmer gesuchtPhase 2
- Providence Portland Medical Center /ID# 277727, Portland
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- Site 02, Portland
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Teilnehmer gesuchtPhase 1
- Research Site, Portland
Study of AVZO-021 in Patients With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Avenzo Therapeutics Recruiting Site, Portland
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Teilnehmer gesuchtPhase 3
- Providence Portland Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
- Oregon Health and Science University, Portland
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Teilnehmer gesuchtPhase 3
- Providence Cancer Institute Franz Clinic, Portland
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Teilnehmer gesuchtPhase 2
- Providence Cancer Institute, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Teilnehmer gesuchtPhase 1
- Providence Portland Medical Center, Portland
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Teilnehmer gesuchtPhase 3
- Site 0105, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- Providence Cancer Institute, Portland
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Teilnehmer gesucht
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- und 2 weitere
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Teilnehmer gesuchtPhase 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- und 2 weitere
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Teilnehmer gesuchtPhase 1/2
- Compass Oncology - Rose Quarter, Portland
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Oregon Health & Science University, Portland
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Providence Cancer Institute Franz Clinic, Portland
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- Providence Cancer Institute Franz Clinic, Portland
- Providence Oncology and Hematology Care Clinic - Westside, Portland
- Providence St. Vincent Medical Center- Investigational Drug Services, Portland
- und 1 weitere
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Teilnehmer gesuchtPhase 3
- Legacy Medical Group Gynecologic Oncology, Portland
- Providence Cancer Center Oncology, Portland
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Teilnehmer gesuchtPhase 2
- USA15-0, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- Oregon Health Sciences University, Portland
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Teilnehmer gesuchtPhase 2
- SCRI - Northwest Cancer Specialists, P.C., Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Teilnehmer gesuchtBeobachtungsstudie
- Massive Bio SYNERGY-AI site, Portland
Eierstockkrebs-Studien in anderen Städten
- Houston, TX89 Studien
- New York City, NY69 Studien
- Boston, MA61 Studien
- Los Angeles, CA50 Studien
- Nashville, TN49 Studien
- Arlington, VA46 Studien
- Philadelphia, PA44 Studien
- Columbus, OH39 Studien
- St. Louis, MO38 Studien
- Chicago, IL36 Studien
- San Antonio, TX31 Studien
- Cleveland, OH30 Studien
Weitere Studien in Portland
- Nichtkleinzelliges Lungenkarzinom46 Studien
- Krebs (alle Arten)34 Studien
- Brustkrebs33 Studien
- Prostatakrebs33 Studien
- Metastasierender Krebs29 Studien
- Kolorektales Karzinom28 Studien
- Lungenkrebs26 Studien
- Akute myeloische Leukämie25 Studien
- Endometriumkarzinom24 Studien
- Plattenepithelkarzinom im Kopf-Hals-Bereich19 Studien
- Bauchspeicheldrüsenkrebs19 Studien
- Herzinsuffizienz17 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.